BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : B01D 9/00 — A1

(11) International Publication Number: WO 00/53282

(43) International Publication Date: 14 September 2000 (14.09.00)

(21) International Application Number: PCT/GB00/00866

(22) International Filing Date: 9 March 2000 (09.03.00)

(30) Priority Data:
9905512.1 10 March 1999 (10.03.99) GB

(71) Applicants *(for all designated States except US)*: SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CARPENTER, Stephen, Thomas [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). WELLMAN, George, Robert [US/US]; SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, Pennsylvania, PA 19406 (US).

(74) Agent: GIDDINGS, Peter, John; SmithKline Beecham, Coporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: CRYSTALLIZATION PROCESS FOR PRODUCING FINE CRYSTAL PRODUCTS

(57) Abstract

The invention relates to a process for the crystallisation of a chemical substance, and more particularly a substance to be used as a pharmaceutically active agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CRYSTALLIZATION PROCESS FOR PRODUCING FINE CRYSTAL PRODUCTS

The present invention relates to a process for the crystallisation of a chemical substance, and more particularly a substance to be used as a pharmaceutically active agent.

Crystallisation is a well known technique for the purification of chemical compounds. Crystalline products prepared using traditional batch methodology may vary; for example in the degree of agglomeration experienced and the habit and size of individual crystals so formed. Moreover, in some circumstances, conventional batch mode crystallisation may give poor results, i.e. produces oils or crystals containing occluded impurities. There is therefore a need for a crystallisation process that gives rise to products of uniform and consistently small crystal size without the problems of batch processing, especially oiling or solvent inclusion. This is particularly true for pharmaceutically active compounds which might otherwise have to be milled to improve their bio-availability, or to increase their suitability in processing, e.g. the electrostatic deposition of active ingredients in tablet manufacture.

According to the present invention there is provided, in a first aspect, a process for the continuous crystallisation of an organic chemical compound which comprises contacting a stream of either the compound or a salt thereof dissolved in a solvent with a stream of anti-solvent or colder solvent, or a solution of an appropriate acid or base, and separating off the crystals formed.

Preferably the solute/solvent/antisolvent system will be one which has a fast precipitation time, as this gives rise to particularly small crystals. By 'precipitation time', we mean the time taken to observe precipitation in a mixed system e.g. cloudiness. Precipitation times can be determined by mixing and observing precipitation in individual solvent systems. Preferably the precipitation time will be less than 1 minute, especially less than 5 seconds, and particularly less than 1 second.

Precipitation times may be varied by adjusting the concentration of solute, the rates of flow of solution and anti-solvent, and the temperatures of the solvent and anti-solvent.

It should be recognised that the process of crystallisation can involve the initial formation of amorphous solid particles which rapidly change into a crystalline form.

For some applications it may prove satisfactory for the contacting process to be undertaken using a simple three-way pipe connection (for example a 'T' or 'Y'-connection) provided that appropriate flow rates are used. Preferably, however, the contacting process is undertaken using conditions of high shear and turbulence.

Mixing devices suitable for use in this invention include known in-line mixers, e.g. of the type in which one or more turbulence-creating elements are located within a pipeline through which the components are caused to flow. Another suitable type of mixer is a homogeniser, e.g. of the type in which two liquid phases are forced under pressure through a biased valve. Suitable mixing devices may also include cavities subjected to high turbulence and or shear stress by means of turbines, propellers etc.

Another and preferred type of mixer for creating conditions of high shear and turbulence is a chamber wherein introduced fluids are subjected to intense rotational swirling, for example a vortex chamber of the type disclosed generally in EP-0153843-A (UK Atomic Energy Authority), the contents of which are incorporated herein by reference. The vortex chamber comprises a chamber of substantially circular cross section, e.g. generally cylindrical in shape, and having tangential inlets and an axial outlet. In such a mixer, the components are introduced via the tangential inlets where they experience swirling and intense mixing as they radially accelerate towards the centrally located outlet.

Preferably a vortex mixer (e.g. a Power Fluidics mixer) is used to create the conditions of high shear and turbulence. Preferably, the mixing is carried out under controlled residence times in the mixer as this gives rise to a product of uniform crystal size. Fast precipitation times give rise to particularly small crystals. Each stream is fed at high velocity into the central mixing chamber where it is mixed and accelerated towards to the central exit orifice. The internal diameter of such a vortex chamber is about 8 mm, and its height about 1mm. A combination of small mixing chamber volume (approx. 0.05-0.1ml) and high throughputs (preferably between 0.5L and 2L/min) generate typical residence times of less than 10ms in a steady-state environment where all elements of the mixed stream experience

minimal forward and backmixing. This effectively fixes supersaturation levels within the device with resultant tight control of particle size. Alternative dimensioned mixers may be used provided that the flow-rates can be sufficiently modulated to maintain high turbulence and uniform supersaturation conditions at similar residence times. By way of contrast, changes in supersaturation levels will typically occur in a conventional batch stirred reactor due to non-ideal mixing behaviour and both axial and radial heat gradients throughout the system.

Optionally the mixed stream of solute in solvent and anti-solvent is cooled during the mixing process and/or subsequent to it before the crystalline material is separated from the solvent stream. Optionally, in order to selectively control the size of the particles produced, the outlet flow from the mixer (e.g. the Power Fluidic mixer) can be passed through one or more tubular reactors (e.g. a flexible tubular reactor) before the crystals are separated off. Optionally such tubular reactors are cooled.

Preferably the compound to be crystallised is an active ingredient for a pharmaceutical composition. Particularly preferred compounds for crystallisation in accordance with the process of this invention are:
Eprosartan methanesulphonate - (-(E)-(-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid methanesulphonate); and
Nabumetone - 4-(6-methoxy-2-naphthalenyl)-2-butanone.

Preferably, the process is one in which the compound to be crystallised is the same as the compound dissolved in the solvent prior to addition of the anti-solvent (e.g. neutral molecule, free acid or base, acid-addition salt or base-addition salt). However the process can also be used where a solution containing the free acid or base of a compound is mixed under conditions of high turbulence with a solvent containing either acid or base to form a salt, or alternatively where a solution of a salt of a compound is rapidly mixed under conditions of high turbulence with a solvent containing an acid or base.

The utility of the invention will now be described by way of example and with reference to the accompanying drawings, in which:

Figure 1 Shows a mixing device in the form of a vortex chamber having two tangential inlets and an axial outlet;

Figure 2 Shows crystals of Eprosartan methanesulphonate obtained by batch crystallisation;

Figure 3 Shows crystals of Eprosartan methanesulphonate prepared by continuous crystallisation using a vortex mixer;

Figure 4 Shows a comparison of particle sizes of Eprosartan methane sulphonate produced by continuous crystallisation and batch crystallisation;

Figure 5 Shows crystals of Nabumetone obtained by batch crystallisation;

Figure 6 Shows crystals of Nabumetone prepared by continuous crystallisation using a vortex mixer;

Figure 7 Shows a comparison of particle sizes of Nabumetone crystals produced by continuous crystallisation and batch crystallisation.

Example 1

Eprosartan methanesulphonate - (-(E)-(-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic acid methanesulphonate) is described in U.S. 5,185,351/EP 0 403 159. Preferably the crystallised eprosartan methanesulphonate has a d_{90} of less than 10 microns.

Preferably the solution of the solute is a solution of Eprosartan methanesulphonate in acetic acid, preferably at an elevated temperature for example from 20°C to 100°C, preferably 70°C to 90°C and especially between 75 to 85°C.

Preferably the solution of the solute is reasonably concentrated, for example between 5 and 40% w/v, preferably between 10 and 30% w/v and especially between 15% and 25% w/v.

Preferably the anti-solvent is ethyl acetate or tert-butyl methyl ether (TBME), especially TBME. Preferably the anti-solvent is used in a significant excess to the solution of solute, for example from a 3-fold to a 30-fold excess, preferably 6-fold to a 25-fold excess.

Preferably the anti-solvent is mixed at a temperature from -20°C to 80°C, preferably 0°C to 30°C, most preferably around 10 °C to 20°C.

Preferably the contacting process is undertaken in a vortex mixer.

It has been found that using a solution of Eprosartan methanesulphonate (concentration of 20%w/v) dissolved in acetic acid at around 80°C and using an anti-solvent of tert-butyl methyl ether at around 20°C, that crystals of a particularly advantageous small and uniform size and consistency are obtained (see Figure 3). Particle size distributions were found to be narrow, uni-modal and near symmetrical with d_{10}, d_{50} and d_{90} values of 1, 3.5 and 7 micron respectively. There is good demonstrated reproducibility with no observed agglomeration. By comparison, the slow controlled addition of Eprosartan methanesulphonate /acetic acid solution to excess tert-butyl methyl ether with vigorous stirring in a semi-batch mode environment without use of a vortex mixer leads to a much broader size distribution of the generated particles (see Figure 4).

Example 2

Nabumetone - (4-(6-methoxy-2-naphthalenyl)-2-butanone) is described in US patent 4,061,779. Preferably the crystallised Nabumetone has a needle length of less than 20 microns.

Preferably the solution of the solute is a solution of Nabumetone in propan-2-ol, preferably at an elevated temperature for example from 20°C to 82°C and more preferably between 50°C to 77°C.

Preferably the solution of the solute is at a concentration of 5 to 30%w/v, more preferably between 5 and 10%w/v.

Preferably the anti-solvent is water. Preferably the anti-solvent is used in an excess to the solution of solute, for example from a 4-fold to a 30-fold excess, preferably 4-fold to 10-fold.

Preferably the anti-solvent is mixed at a temperature from 0°C to 50°C, more preferably 6°C to 27°C.

Preferably the contacting process is undertaken in a vortex mixer.

It has been found that using a solution of Nabumetone (concentration of 5%w/v) dissolved in hot propan-2-ol and using water as an anti-solvent, that crystals of a particularly advantageous small and near-uniform size and consistency are obtained. Particle size distributions were found to be narrow, uni-modal and near symmetrical

with d_{10}, d_{50} and d_{90} values of 2, 5 and 12 micron respectively (Figures 6 & 7). There is good demonstrated reproducibility with no observed agglomeration.

Claims:

1. A process for the continuous crystallisation of an organic chemical compound which comprises contacting a stream of either the compound or a salt thereof dissolved in a solvent with a stream of anti-solvent or colder solvent, or a solution of an appropriate acid or base, and separating off the crystals formed.

2. A process according to Claim 1 in which the contacting process is undertaken using conditions of high shear and turbulence.

3. A process according to Claims 1 or 2 in which the solute/solvent/antisolvent system has a precipitation time of less than 5 seconds.

4. A process according to any one of Claims 1 to 3 in which a vortex mixer or a three-way pipe connection is used to effect mixing.

5. A process according to any one of Claims 1 to 4 in which the compound is not converted into a different salt form.

6. A process according to any one of Claims 1 to 5 in which the compound is Eprosartan methanesulphonate using acetic acid as solvent and tert-butyl methyl ether as anti-solvent.

7. A process according to any one of Claims 1 to 5 in which the compound is Nabumetone using propan-2-ol as solvent and water as antisolvent.

8. A process according to any one of Claims 1 to 7 in which the compound to be crystallised is an active ingredient for a pharmaceutical composition.

9. A crystalline compound having small and uniform crystal size prepared by a process according to any one of Claims 1 to 8.

10. Crystalline Eprosartan methanesulphonate with a d_{90} value of less than 10 micron.

11. Crystalline Nabumetone with a d_{90} value of less than 20 micron.

Figure 1

Figure 2



Figure 3


Comparison: Vortex Mixer - Semi-batch Reactor
volume size distribution density [%/microns]
25
20
15
10
5
0
0
10
20
30
40
50
60
70
80
90
100
particle size [microns]
vortex mixer
semi-batch reactor

Figure 4



Figure 5



Figure 6


Comparison: Nabumetone crystallisation:
Vortex Mixer - Batch
volume size distribution density [%/microns]
particle size [microns]
vortex mixer
batch crystallisation
0
2
4
6
8
10
12
14
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200

Figure 7

INTERNATIONAL SEARCH REPORT

Inter onal Application No
PCT/GB 00/00866

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 B01D9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 461 930 A (MERCK & CO INC) 18 December 1991 (1991-12-18) the whole document	1,2,4-11
X	WO 96 32095 A (ASTRA AB ;JAKUPOVIC EDIB (SE); TROFAST JAN (SE)) 17 October 1996 (1996-10-17) page 4, line 14 -page 10	1,2,4-11
X	WO 94 07582 A (MERCK & CO INC ;DAUER RICHARD (US); MOKRAUER JONATHAN E (US); MCKE) 14 April 1994 (1994-04-14) page 8, line 16 -page 9, line 12; figure 1	1,2,4-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
6 June 2000	15/06/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3018	Plaka, T

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter ...nal Application No
PCT/GB 00/00866

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0461930 A	18-12-1991	CA 2044706 A	16-12-1991
		DE 69112917 D	19-10-1995
		DE 69112917 T	15-05-1996
		ES 2078447 T	16-12-1995
		IE 67187 B	06-03-1996
		JP 4231960 A	20-08-1992
		US 5314506 A	24-05-1994
WO 9632095 A	17-10-1996	AU 694863 B	30-07-1998
		AU 5352496 A	30-10-1996
		CA 2217062 A	17-10-1996
		CN 1186428 A	01-07-1998
		EP 0820276 A	28-01-1998
		JP 11503448 T	26-03-1999
		NO 974557 A	02-10-1997
		NZ 305515 A	29-03-1999
		ZA 9602596 A	14-10-1996
WO 9407582 A	14-04-1994	AT 161742 T	15-01-1998
		AU 668246 B	26-04-1996
		AU 5293993 A	26-04-1994
		CA 2143116 A	14-04-1994
		DE 69316229 D	12-02-1998
		DE 69316229 T	06-08-1998
		EP 0663845 A	26-07-1995
		FI 951613 A	05-04-1995
		JP 8501982 T	05-03-1996
		NO 951321 A	05-04-1995
		US 5578279 A	26-11-1996